

*Not for release to US wire services or distribution in the US*

## Successful completion of Retail Entitlement Offer

Radiopharm Theranostics Limited (**ASX:RAD, RAD or the Company**), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the successful completion of the retail component of the fully underwritten 1 for 3.55 pro-rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) announced by the Company on 19 October 2022. New fully paid shares under the Entitlement Offer (**New Shares**) will be issued at a price of \$0.14, together with 1 free attaching option for every 1 New Share issued, each with an exercise price of \$0.20 and exercisable on or before 30 November 2026 (**New Options**).

### Retail Entitlement Offer

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) closed at 5:00pm (Sydney time) on Friday, 18 November 2022, raising gross proceeds of approximately \$1.2 million. Eligible retail shareholders took up 8,705,317 New Shares.

23,367,918 New Shares not subscribed for under the Retail Entitlement Offer (**Shortfall Shares**) will be subscribed for by Bell Potter Securities Limited (**Underwriter**) or sub-underwriters, in accordance with the underwriting agreement between the Company and the Underwriter dated 20 October 2022.

Completion of the Retail Entitlement Offer represents the final stage of RAD's approximately \$10 million (before costs) Entitlement Offer. The institutional component of the Entitlement Offer (**Institutional Entitlement Offer**) attracted strong support and was successfully completed on Thursday, 20 October 2022, raising gross proceeds of approximately \$5.5m.

The New Shares to be issued under the Retail Entitlement Offer will rank equally with existing RAD fully paid ordinary shares in all respects. New Shares and New Options under the Retail Entitlement Offer and Shortfall Offer, and New Options under the Institutional Entitlement Offer, are expected to be issued on Friday 25 November 2022 and commence normal trading on the ASX on Monday, 28 November 2022.

### Key Dates

The timetable below is indicative only and subject to change. The Company reserves the right to alter the dates below in its full discretion and without prior notice, subject to the ASX Listing Rules and the Corporations Act.

Allotment of New Shares issued under the Retail Entitlement Offer and New Options issued under the Entitlement Offer	Friday, 25 November 2022
Despatch of holding statements for New Shares and New Options issued under the Retail Entitlement Offer	Monday, 28 November 2022
Normal ASX trading for New Shares issued under the Entitlement Offer commences	Monday, 28 November 2022

The Directors wish to thank all shareholders for their continued support.

**Phillip Hains  
Company Secretary**

**Not an offer in the United States**

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.